Skip to main content
Premium Trial:

Request an Annual Quote

Aclara BioSciences Second Quarter Revenues Drop

NEW YORK, July 30 -- Aclara BioSciences of Mountain View, Calif., today announced revenues of $405,000 for the second quarter ending June 30, compared to $673,000 for the year-ago quarter.


The company reported research and development expenditures of $4.1 million, compared to $6.6 million for the same quarter in 2002.


The firm reported cash, cash equivalents, and short term investments of $73.6 million, compared to the $51 million it reported as of Dec. 31.


The company had a net loss of $5.1 million, compared to $9.9 million for the year-ago period.


The company said it reduced operating expenses by $5.6 million, with $3.8 million in savings from the reduction of its microfluidics programs, a reorganization, and a decision to focus on its eTag Assay product line. The firm also saved $1.8 million by eliminating settlement expenses.


The Scan

Back as Director

A court has reinstated Nicole Boivin as director of the Max Planck Institute for the Science of Human History, Science reports.

Research, But Implementation?

Francis Collins reflects on his years as the director of the US National Institutes of Health with NPR.

For the False Negatives

The Guardian writes that the UK Health Security Agency is considering legal action against the lab that reported thousands of false negative COVID-19 test results.

Genome Biology Papers Present Epigenetics Benchmarking Resource, Genomic Architecture Maps of Peanuts, More

In Genome Biology this week: DNA methylation data for seven reference cell lines, three-dimensional genome architecture maps of peanut lines, and more.